From: Recent developments in multiple sclerosis therapeutics
Agent | Proposed mechanisms of action | Stage of development* |
---|---|---|
Alemtuzamab | Leukocyte depletion; Depletes CD52 B and T cell populations, monocytes, macrophages and eosinophils | Phase III for RRMS |
Daclizumab | Leukocyte depletion; Binds cell-surface receptor IL2; reduces T cell proliferation and activation | Phase II for RRMS |
Rituximab | B cell-directed therapy; Depletes CD20 B cell population | Phase III for RRMS |